<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SDU-Denmark_Tour20 skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SDU-Denmark/Tour20</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="BackgroundLayout"><DIV class="top bannerShadow"><DIV class="NavbarContainer"><DIV class="NavbarContainerInner"><DIV class="MenuButton" id="btnWelcome"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark">Welcome</A></DIV><DIV class="MenuButton" id="btnTour"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Interactive wiki-tour</A></DIV><DIV class="MenuButton" id="btnMenu"><A class="MenuButtonLink" href="#" id="btnMenu2">Menu</A><DIV class="menuPopup"><DIV class="menuPopupContent"><DIV class="menuPopupContentInner bannerShadow"><DIV class="menuIntro"><DIV class="warningBox"><P class="menuIntro">
You really should try our <A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">interactive wiki tour</A> instead! 

</P></DIV><P class="menuIntro">
But if you are looking for a specific page - you are in the right place. 
</P><DIV class="menuItems"><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Introduction</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour11">The Team</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour12">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour13">Gallery</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour14">Medal Requirements</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour20"> Antibody Issue</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour21">Antibody Production</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour22">Animal Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour23">The Alternative</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour30">PAST</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour31">Two-Hybrid Screening</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour32">System Design</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour33">Business</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour34">Entrepreneurship</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour40">Process</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour41">Complete Journal</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour42">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour43">SOPs</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour44">Safety</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour50">Results</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour51">Characterization</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour52">Two-Hybrid System</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour53">Submitted Parts</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour54">Interlab Study</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour60">Practices</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour61">Survey</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour62">Education</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour63">Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour64">A Children's Book</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour70">
What is Next?</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour71">Challenges and Limitations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Medical Aspects</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Lab Work</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour73">The End</A></LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="tourBoundingBox"><DIV class="tourBoundingBoxInner bannerShadow"><DIV class="parentTourItem "><A class="tourItemLabel" title="Get a brief overview of the project.">
                Introduction
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="Would you like to meet our team?">
                       The Team
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="To express our thankfulness.">
                        Attributions
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Gallery
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medal Requirements
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               Antibody issue
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Antibody production
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Animal Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        The Alternative
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                PAST            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Two-Hybrid Screening
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        System Design
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Business
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Entrepreneurship
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                Process
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Complete Journal
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Collaborations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       SOPs
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Safety
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">       Results
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Characterization
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      Two-Hybrid System
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Submitted Parts
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Interlab Study
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
Practices
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Survey
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Education
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title=""> A Children’s Book
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               What is Next
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Challenges and Limitations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medical Aspects
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Lab Work
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      The End
                    </A></DIV></DIV></DIV></DIV></DIV><DIV class="MainLayout"><DIV class="content"><P><I> &quot;The future depends on what you do today.”
― <B>Mahatma Gandhi</B></I></P><H2 align="center"> The antibody issue </H2><DIV class="thumb tright"><DIV class="thumbinner" style="width:155px;height:255px;"><DIV class="thumbcaption">Figure 1: A predicted Peptide Aptamer structure using Phyre<SUP>2</SUP>.
</DIV></DIV></DIV><P><SPAN class="intro"> Since 1975</SPAN>, where Kohler and Milstein initiated the current era of antibody production by introducing the hybridoma technology, the applications have continuously been extended and mAbs have become an essential part in many aspects of resear<SPAN class="sourceReference">ch</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Liu JK1 (2014) The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Sep 11;3(4):113-6. DOI: 10.1016/j.amsu.2014.09.001. 
   <A target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/ "> [PubMed] </A></SPAN>

The production is a bio engineered process carried out in mammalian cells. Despite several advantages, some drawbacks of using mammalian cells are often disregarded: they are cumbersome, costly and at the expence of animal lifes. Foremost requirements for a system capable of making mAbs are high growth rate and high production yield. The demand is continuously growing and the production market is exponentially rising. In the end of 2014, 47 mAbs have been approved for treatment in US and Europe and this number is estimated to be ~70 in 2020, with a world-wide revenue at nearly $125 billi<SPAN class="sourceReference">on</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Dawn M Ecker, Susan Dana Jones &amp; Howard L Levine (2015) The therapeutic
monoclonal antibody market, mAbs, 7:1, 9-14, DOI: 10.4161/19420862.2015.989042 
   <A target="_blank" href="http://dx.doi.org/10.4161/19420862.2015.989042"> [PubMed] </A></SPAN> Eager to read more about the current production methods? Go to <A href="http://www.ncbi.nlm.nih.gov/pubmed/25529996"> Antibody Production</A>. 
</P><DIV class="thumb tright"><DIV class="thumbinner" style="width:155px;height:240px;"><DIV class="thumbcaption">Figure 2: A traditional antibody
</DIV></DIV></DIV><P><SPAN class="intro">We find</SPAN> it important to consider the cost, effectiveness and not at least the ethics that are connected to the use of animal cells. The effectiveness of antibodies is high, however, so is the cost. Despite strict control and legislation in Denmark regarding animal conditions, an alternative to laboratory animals will always be preferable. Furthermore 
the decade long search for alternatives to animals in research implies that scientists also find the existing method 
controversial. Read our page <A href="https://2015.igem.org/Team:SDU-Denmark/Tour22">Animal Ethics</A> for more information about this.
</P><P><SPAN class="intro">Peptide aptamers are molecules</SPAN> consisting of a scaffold protein with a variable loop (<A href="#Figure1">Figure 1</A>), which make them perfect in the search for an alternative to traditional antibodies (<A href="#Figure2">Figure 2</A>). The variable part can function as the heavy and light chains of an antibody, in which the variable loop functions as the antigen binding region. 


By manipulating <I>Escherichia coli</I> into producing peptide aptamers many of the drawbacks by using mammalian cells will be minimized. Read more at <A href="https://2015.igem.org/Team:SDU-Denmark/Tour23">The Alternative</A>. 
</P></DIV><DIV class="footer "><DIV class="footerContainer"><A class="footerBtn footerShadow" id="btnFastForward"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnNextChapter"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnDigDeeper"><P class="footerBtnPre">Dig deeper
</P></A><A class="footerBtn footerShadow" id="btnTheEnd" href="http://www.igem.org" target="_blank"><P class="footerBtnPre">End of tour
</P><P class="footerBtnHeader" style="text-transform: none !important;">Want more? Go to iGEM.org!</P><P class="footerBtnText">
If you want to learn more about Synthetic Biology you should visit iGEM's homepage, which contains loads on the subject. You can even visit other teams' wikis and take a look at what they accomplished. Or maybe join a team yourself?</P></A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>